Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 456 participants.
Also called NCT07876544
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 456 participants
- Registry
-
NCT07876544
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07876544. Randomized; double masking; primary purpose treatment. Start 2026-09-22 (actual); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage
- Acronym
- SABER
- Condition
- Hypertension
- Intervention (Drug)
- Sitogilun Malate
- Intervention (Drug)
- Allisartan Isoproxil
- Intervention (Drug)
- Amlodipine besylate
- Intervention (Drug)
- Sitogilun Malate Placebo
- Intervention (Drug)
- Allisartan Isoproxil Placebo
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
Record details
- Record id
cardio:ct-nct07876544- Content hash
65e6fbb8f4fb8d3a5678cedd5eceddcb68f2f30385f89accc8747e1970ce9ec4